Quick Overview
- Consensus estimates call for Q1 earnings per share of $6.05 with revenue reaching $9.76 billion, representing 3.1% growth versus prior year
- Wall Street maintains a Buy rating with average price target of $736.24, suggesting approximately 11% potential upside from current levels near $665
- Primary focus: profitability improvements, with segment operating margins projected to reach approximately 11%
- Latest developments include a $475 million Glide Phase Interceptor contract modification and successful YFQ-48A Talon Blue drone engine test
- Shares have declined 2% in the past month while aerospace and defense peers climbed 10.3%
Northrop Grumman delivers its first quarter 2026 financial results Tuesday morning before markets open. Following an extended period of substantial development expenditures, market participants are asking a critical question: has the profitability turnaround arrived?
Northrop Grumman Corporation, NOC
Analyst consensus projects earnings per share of $6.05 alongside revenue totaling $9.76 billion. These figures represent a sequential decline from the fourth quarter’s $7.23 EPS and $11.7 billion in sales, though such patterns are typical. Defense industry companies routinely deliver their strongest quarterly performance in the final three months of the year.
Compared to the same period last year, revenue projections indicate 3.1% expansion. This would mark a significant improvement from the 6.6% contraction Northrop experienced during Q1 of the previous year.
During the most recent reporting period, the company exceeded expectations on both top and bottom lines. Revenue totaled $11.71 billion, climbing 9.6% year over year. Earnings per share reached $7.23, surpassing the $6.99 analyst forecast. The single disappointment came from full-year earnings guidance, which fell short of Street projections.
Shares currently trade in the $665–$667 range, positioned near the midpoint of the 52-week trading band between $450.13 and $774.00. Wall Street price objectives have been trending upward. Wells Fargo launched coverage with a Buy recommendation and $800 target on March 31. Deutsche Bank elevated its target to $778 on April 8. Jefferies adjusted its Hold-rated objective to $710 on April 9.
Earnings projections have increased 0.51% during the past 60 days. Revenue forecasts have risen 0.24%. While incremental, the trajectory points in a favorable direction.
Profitability Expansion Takes Priority
The central issue approaching Tuesday’s announcement centers on whether margin improvement is materializing in actual results. Wall Street anticipates segment operating margins recovering to the 11% level.
The Aeronautics division benefits from cycling past a B-21 Raider development expense recorded last year, which should provide tailwinds. Mission Systems stands to gain from an enhanced program portfolio. Should both business units deliver as expected, it would confirm that Northrop’s capital-intensive development phase is genuinely transitioning toward profitability.
Full-year earnings guidance remains another area of attention. Current guidance spans $27.40 to $27.90. Analysts anticipate management will maintain that range, although some believe the more compelling growth narrative unfolds in 2027.
Latest Contract Awards Set the Stage
Northrop has maintained an active contract pipeline throughout April. The defense contractor secured a $475 million modification to expedite its Glide Phase Interceptor initiative. Its YFQ-48A Talon Blue autonomous combat platform successfully completed initial engine testing on April 17. Meanwhile, the Sentinel ICBM program continues progressing toward an inaugural flight scheduled for 2027.
Shares have slipped approximately 2% during the past month. The wider aerospace and defense industry has advanced 10.3% over the identical timeframe, positioning Northrop among the underperformers within its peer group entering the earnings announcement.
Industry competitors have already released their results. AAR delivered 24.6% revenue expansion and exceeded projections, sending shares up 9.9%. Byrna achieved 10.9% growth but disappointed on estimates, tumbling 38.3%.
Analysts have largely maintained stable estimates throughout the last 30 days, indicating expectations of a relatively straightforward quarter without significant deviations.
